In this episode, Paul E. Sax, MD, discusses emerging drug therapies and treatment options for patients with HIV, including rapid initiation of ART, long-acting ART, and 2-drug ART regimens. The overview will include analyses from:
- The RAPID ART program in San Francisco, where same-day initiation of ART led to faster HIV-1 RNA suppression that was maintained at greater than 92% during a 3-year period
- The DIAMOND study analyzing virologic efficacy and safety at 48 weeks after initiating DRV/COBI/FTC/TAF within 24 hours of HIV infection diagnosis
- A rapid ART start program in young PWH in New Orleans that demonstrated achievement of viral suppression in fewer than 30 days and no discontinuations due to adverse events
- The ATLAS (including ATLAS-2M) and FLAIR studies that demonstrated efficacy and safety of long-acting injectable CAB plus RPV
- SWORD-1 and SWORD-2 that demonstrated switching to a 2-drug regimen of DTG plus RPV in virologically suppressed adults was safe and effective
- GEMINI-1 and GEMINI-2 that demonstrated noninferiority of DTG plus 3TC compared with DTG plus FTC/TDF
- TANGO that demonstrated safety and efficacy of switching to DTG/3TC in virologically suppressed adults receiving a TAF-based regimen
In addition, Dr. Sax reviews current recommendations by the DHHS, WHO, and IAS-USA regarding these emerging therapies and treatment paradigms.
Presenter:
Paul E. Sax, MD
Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Follow along with the slides at:
https://bit.ly/3zdPwm2
Content based on an online CME program supported by an educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3ux6FF8
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
